THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
It is a new indazole cannabinoid replacement of AM-2201
IUPAC name: 1-(5-fluoropentyl)-1h-indazol-3-yl)-(naphthalen-1-yl)-methanone
Purity: 99,7% min
Appearance: white powder.
The physiological and toxicological properties of this compound are not known. This product is intended for research and forensic purposes.